Compounded Semaglutide vs. Ozempic

Compounded semaglutide and Ozempic both contain the peptide semaglutide, but they are not the same product: Ozempic is a brand-name drug manufactured by Novo Nordisk and approved by the FDA for type 2 diabetes, while compounded semaglutide is prepared by a pharmacy from bulk active ingredient and has not gone through that approval process. The distinction matters because FDA approval is not a label — it is a specific regulatory finding about a specific manufactured product, and that finding does not transfer to a different formulation made somewhere else.

Side-by-side

What the FDA's approval of Ozempic actually covers

The FDA's approval of Ozempic is specific: a particular formulation of semaglutide, manufactured under a particular process, indicated for type 2 diabetes. Semaglutide's chronic weight management indication is approved under the brand name Wegovy, not Ozempic — both are Novo Nordisk products, but they are evaluated and labeled for different uses. When a compounding pharmacy prepares semaglutide from bulk powder, the resulting product has not been through that review. It may use the same peptide sequence, but "same molecule" and "same approved drug" are different claims, and the FDA has been explicit that it does not stand behind compounded versions the way it stands behind the approved brand.

Why compounded semaglutide exists at all

Compounding pharmacies are permitted, under specific federal rules, to prepare a drug from bulk active ingredient when a commercially available product is in shortage or when a prescriber needs a formulation that isn't otherwise sold. That is the legal basis for compounded semaglutide's existence — it is not a parallel approval track, and it does not carry the same inspection and batch-testing requirements that apply to Novo Nordisk's manufacturing. The FDA's page on GLP-1 drugs used for weight loss lays out its specific concerns with this category: inconsistent potency, unverified sterility, and products that combine semaglutide with other ingredients the agency has not evaluated in that combination.

A third category: semaglutide as catalogued material

PeptoClinic's semaglutide is a third thing again — it is neither the approved Ozempic/Wegovy formulation nor a pharmacy's compounded preparation. It is catalogued material, reviewed by a physician as part of a consultation before anything ships, and it is not presented as, and is not, an approved drug. PeptoClinic holds no FDA approval for any compound in its catalogue, semaglutide included, and makes no claim that its material is equivalent to Ozempic or Wegovy. What PeptoClinic does state plainly: the purity standard claimed across its catalogue is ≥99% by HPLC, detailed on the quality page, and current pricing for everything in the catalogue is published on the pricing page rather than quoted case by case.

Where this leaves a reader comparing the two

If the question is "which one has gone through the FDA's review for safety and effectiveness," the answer is Ozempic — that review is what the approval represents, and it is specific to Novo Nordisk's manufactured product. If the question is "is compounded semaglutide the same thing with a different label," the honest answer from the regulator is no: the FDA has not evaluated compounded versions as finished drug products, and it has said so directly. Material ordered through a catalogue like PeptoClinic's falls under neither heading — it is not the approved brand, and it is not a pharmacy's compounded preparation of it. Orders to U.S. addresses are handled as described on the shipping page.